Seven Bridges Advisors LLC decreased its position in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 27.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,037 shares of the biopharmaceutical company’s stock after selling 770 shares during the period. Seven Bridges Advisors LLC’s holdings in Alexion Pharmaceuticals were worth $238,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Pioneer Investment Management Inc. raised its position in Alexion Pharmaceuticals by 30.3% in the fourth quarter. Pioneer Investment Management Inc. now owns 41,785 shares of the biopharmaceutical company’s stock valued at $7,970,000 after buying an additional 9,723 shares in the last quarter. Capstone Asset Management Co. raised its position in Alexion Pharmaceuticals by 5.5% in the first quarter. Capstone Asset Management Co. now owns 23,478 shares of the biopharmaceutical company’s stock valued at $3,269,000 after buying an additional 1,218 shares in the last quarter. CrestPoint Capital Management LLC raised its position in Alexion Pharmaceuticals by 8.7% in the first quarter. CrestPoint Capital Management LLC now owns 2,500 shares of the biopharmaceutical company’s stock valued at $348,000 after buying an additional 200 shares in the last quarter. Raymond James Trust N.A. raised its position in Alexion Pharmaceuticals by 0.9% in the first quarter. Raymond James Trust N.A. now owns 3,625 shares of the biopharmaceutical company’s stock valued at $505,000 after buying an additional 32 shares in the last quarter. Finally, OLD National Bancorp IN raised its position in Alexion Pharmaceuticals by 12.2% in the first quarter. OLD National Bancorp IN now owns 8,204 shares of the biopharmaceutical company’s stock valued at $1,142,000 after buying an additional 891 shares in the last quarter. 96.34% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 1.04% during mid-day trading on Wednesday, reaching $130.36. 1,210,394 shares of the company’s stock were exchanged. The firm has a market capitalization of $29.23 billion, a P/E ratio of 327.54 and a beta of 1.08. The stock has a 50-day moving average of $131.16 and a 200 day moving average of $135.82. Alexion Pharmaceuticals Inc. has a one year low of $110.56 and a one year high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The business had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. During the same quarter in the previous year, the business earned $1.44 earnings per share. The firm’s revenue was up 18.4% on a year-over-year basis. On average, analysts forecast that Alexion Pharmaceuticals Inc. will post $4.65 EPS for the current fiscal year.

Several equities analysts have commented on the stock. Vetr lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $171.50 target price on the stock. in a report on Thursday, June 2nd. Brean Capital restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. Morgan Stanley restated an “overweight” rating and issued a $189.00 price target (down from $203.00) on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $221.00 price target (down from $228.00) on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. Finally, BMO Capital Markets restated a “buy” rating and issued a $160.00 price target (down from $168.00) on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $182.85.

In other Alexion Pharmaceuticals news, CFO Vikas Sinha sold 277 shares of the stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $37,987.78. Following the transaction, the chief financial officer now directly owns 178,463 shares in the company, valued at $24,474,415.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David Hallal sold 332 shares of the stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $45,530.48. Following the transaction, the chief executive officer now owns 189,266 shares in the company, valued at $25,955,939.24. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals Inc. (NASDAQ:ALXN).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.